Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Tildrakizumab in the Treatment of Genital Psoriasis in Austria, Switzerland, and the Czech Republic

NCT06029257 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT06029257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06029257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Tildrakizumab in the Treatment of Genital Psoriasis in Austria, Switzerland, and the Czech Republic
Lead sponsor
Almirall, S.A.
Phase
Observational
Overall status
Recruiting
Start date
November 14, 2023
Completion date
March 31, 2026
Enrollment
110 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genital psoriasis